

#### Overview


Standard Grade biospecimens are samples obtained from biospecimen network that can be used to study personalized medicine, drug and diagnostics development, or specifically for high-throughput validation of diagnostic tests and platforms. Our capability is to accelerate your time to market without having to compromise on quality and clinical data integrity. A comprehensive range of high-quality samples is available to meet your specific needs at every stage of your research and drug development process.

For our Standard Grade biospecimens, tissue is collected from clinical institutions using a local protocol for resection and tissue preservation. Quality assessment performed by our certified in-house pathologists guarantees that the risk factors often associated with tissue samples, such as poor tissue or block quality, insufficient tumor cell content, or high levels of necrosis, are reduced. We enable access to thousands of routine pathology samples through our global external biospecimen network that comprises selected hospitals and partners across Europe, North America, and Asia. A broad spectrum of systematic sample quality and clinical data is provided, ranging from the most stringent requirements to routine and standard operations.



### **Your Benefits**

- Basic clinical data provided with every biospecimen
- Biomarkers and mutation status data available for selected cohorts
- Full range of cancer entities available including normal tissues
- Lowest usability failure rate (< 1 %) of quality controlled biospecimens performed by in-house pathologists
- Large biospecimen repository and special procurement services
- Informed patient consent available for selected cohorts







# **Biospecimen Types**



### Tissue - tumor

Formalin-fixed paraffin-embedded (FFPE)

Our team will assist you to select the most suitable biospecimen to match your needs.

## **Clinical Data**

We offer a basic data package that includes date of birth, gender, organ, histological type, tumor content, and TNM. Additional data is available for selected cohorts:

 Additional data (e.g., biomarker status): MSI, MSS, KRAS, BRAF; NRAS for CRC/ rectum carcinoma



